# CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

> **NCT05733000** · PHASE2 · RECRUITING · sponsor: **Northwestern University** · enrollment: 94 (estimated)

## Conditions studied

- Advanced Biliary Tract Carcinoma
- Advanced Colorectal Carcinoma
- Advanced Gastroesophageal Junction Adenocarcinoma
- Advanced Lung Adenocarcinoma
- Advanced Malignant Solid Neoplasm
- Advanced Ovarian Carcinoma
- Advanced Pancreatic Carcinoma
- Advanced Urothelial Carcinoma
- Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Metastatic Biliary Tract Carcinoma
- Metastatic Colorectal Carcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Metastatic Lung Adenocarcinoma
- Metastatic Ovarian Carcinoma
- Metastatic Pancreatic Carcinoma
- Metastatic Urothelial Carcinoma
- Refractory Biliary Tract Carcinoma
- Refractory Colorectal Carcinoma
- Refractory Gastroesophageal Junction Adenocarcinoma
- Refractory Lung Adenocarcinoma
- Refractory Ovarian Carcinoma
- Refractory Pancreatic Carcinoma
- Refractory Urothelial Carcinoma
- Stage II Pancreatic Cancer AJCC v8
- Stage III Colorectal Cancer AJCC v8
- Stage III Lung Cancer AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Devimistat
- **DRUG:** Fluorouracil
- **DRUG:** Gemcitabine Hydrochloride
- **DRUG:** Hydroxychloroquine
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT05733000
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-08
- **Primary completion:** 2028-01-04
- **Final completion:** 2030-03-04
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2023-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05733000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05733000, "CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05733000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*